Yes / Purpose: Dexibuprofen is an enantiomer of ibuprofen with low bioavailability which results
from its hydrophobic nature. Nanosuspensions have developed a podium to solve the in vitro
dissolution problem that frequently occurs in current research.
Materials and methods: The drug and polymer solutions were mixed in a microchannel
fluid reactor and the successive embryonic nanosuspension was decanted into a vial having the
polymer solution. The impact of different process and formulation parameters including inlet
angle, antisolvent and solvent flow rate(s), mixing time, drug concentration, polymer type and
concentration was evaluated.
Results and discussion: Stable dexibuprofen nanocrystals with a particle size of 45±3.0 nm
and polydispersity index of 0.19±0.06 were obtained. Differential scanning calorimetry and
powder X-ray diffraction confirmed the crystallinity. The key parameters observed were inlet
angle 10°, antisolvent to solvent volume of 2.0/0.5 mL/min, 60 minutes mixing with 5 minutes
sonication, Poloxamer-407 with a concentration of 0.5% w/v and drug concentration (5 mg/mm).
The 60-day stability studies revealed that the nanocrystals were stable at 4°C and 25°C. The
scanning electron microscopy and transmission electron microscopy images showed crystalline
morphology with a homogeneous distribution.
Conclusion: Stable dexibuprofen nanocrystals with retentive distinctive characteristics and
having marked dissolution rate compared to raw and marketed formulations were efficiently
fabricated. In future perspectives, these nanocrystals could be converted to solid dosage form
and the process can be industrialized by chemical engineering approach
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/17494 |
| Date | 06 November 2019 |
| Creators | Khan, J., Bshir, S., Khan, M.A., Mohammad, Mohammad A., Isreb, Mohammad |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Published version |
| Rights | © 2018 Khan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)., CC-BY-NC |
Page generated in 0.0016 seconds